$80 Million upfront plus +$1.5 Billion milestones $CTMX Collaboration w/ Astellas - Bispecific antibodies targeting CD3. They will utilize CytomX's Probody platform Sympathy play πŸ‘‰πŸΌ $APVO : APVO436 is Aptevo’s lead bispecific antibody candidate. It is a novel anti-CD123 by anti-CD3 bispecific antibody..." ir.cytomx.com/node/9591/pdf
  • 7
  • 5